4. Duplicata of the letter in contact with the manufacturer, whose premises, equipment types must be accepted on loan. A credit license and third-party pharmaceutical manufacturing are similar in many ways. The difference lies in the type of contract/contract. You need a loan license agreement in a pharmaceutical manufacturing credit license. Under this pressure, the marketing company prints its name and address under “market after” and “manufactured by”. The production company will print its name and address under the “manufactured by” column. This is a process of renting or leasing premises for the manufacturing process. The loan licence application should be submitted individually in structures 24A, 27A with Rs-200/ – or 600// The applicant must obtain a letter from the licensee and present the offices to be used for manufacturing. The receiving authority must be satisfied that the licensee must have the necessary equipment, the limitation of staff with respect to the manufacture and means of verifying a credit licence. For multinationals operating in India, such a measure would be negative, as the percentage of drugs or third parties produced by credit licenses on total production is between 50 and 90%, said a Mumbai-based analyst, on condition of anonymity. IDMA said that more than 40% of drug production is generated by credit licenses.
The production facility that offers loan licenses is also subject to the authorisation of regulators to guarantee quality fidelity and, therefore, quality should not be of concern to the government. Each state government appoints licensing specialists to issue licenses for the production, distribution and supply of medicines or cosmetics for a pre-defined territory and, furthermore, to drop or suspend the licence. The registration of branded drugs is an intellectual property. Intellectual property does not require information on technical details, composition or active substances. Branding of drugs has been at the centre of the debate. The government wanted to introduce measures to regulate credit licenses and third-party pharmaceutical production in India. “The granting of a credit license is an opportunity for the production and marketing company. This restriction (proposal to discontinue credit licences) has a sudden impact on the balance.
The benefit of using existing production capacity for more products and vice versa will be affected. Overall, the benefit of receiving a cheap product for patients is becoming increasingly difficult,” said C.T. Renganathan, Managing Director of RPG Life Sciences Ltd. Contract manufacturing is a process that establishes an agreement between two companies. As part of the agreement, a company manufactures parts or other customer-specific materials on behalf of its customer. In most cases, the manufacturer also supports the ordering and shipping processes for the customer. Mumbai: The government`s proposal to end third-party licensing or credit licenses in the pharmaceutical sector has been criticized by the industry on the grounds that such a measure would result in a loss of revenue for small and medium-sized enterprises (SMEs), disrupt supply and render installed capacity useless.